Search

Author/Creator Mark, Thomas

1. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Issue 7 (15th April 2019)

Authors:
Pratley, Richard E.; Emerson, Scott S.; Franek, Edward; Gilbert, Matthew P.; Marso, Steven P.; McGuire, Darren K.; Pieber, Thomas R.; Zinman, Bernard; Hansen, Charlotte T.; Hansen, Melissa V.; Mark, Thomas; Moses, Alan C.; Buse, John B.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 21:Issue 7(2019)
Page Start:
1625
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial. (1st January 2021)

Authors:
Tarride, Jean-Eric; Husain, Mansoor; Andersen, Andreas; Gundgaard, Jens; Luckevich, Maria; Mark, Thomas; Wagner, Lily; Pieber, Thomas R.
Journal:
Journal of medical economics
Issue:
Volume 24:Number 1(2021)
Page Start:
1318
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). (December 2020)

Authors:
Amod, Aslam; Buse, John B; McGuire, Darren K; Pieber, Thomas R; Pop-Busui, Rodica; Pratley, Richard E; Zinman, Bernard; Hansen, Marco Bo; Jia, Ting; Mark, Thomas; Poulter, Neil R
Journal:
Diabetes & vascular disease research
Issue:
Volume 17:Number 6(2020:Nov.)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗